Table 3. Multivariate prognostic analysis of DFS and OS.
| Characteristics | DFS | OS | ||
| P value | HR(95%CI) | P value | HR(95%CI) | |
| AJCC T Stage | 0.961 | 0.992 | ||
| 1 | 1 | 1 | ||
| 2 | 0.925(0.413–2.069) | 0.939(0.302–2.920) | ||
| 3–4 | 0.800(0.140–4.564) | 0.901(0.074–10.997) | ||
| AJCC N Stage | 0.930 | 0.817 | ||
| 0 | 1 | 1 | ||
| 1 | 1.058(0.430–2.607) | 0.829(0.203–3.384) | ||
| 2 | 1.150(0.309–4.272) | 1.852(0.371–9.250) | ||
| 3 | 1.708(0.351–8.300) | 1.433(0.156–13.136) | ||
| Grade | 0.212 | 0.768 | ||
| 1 | 1 | 1 | ||
| 2 | 2.429(0.903–6.531) | 1.618(0.441–5.930) | ||
| 3 | 1.815(0.558–5.905) | 1.321(0.281–6.212) | ||
| Subtype | 0.012* | 0.043* | ||
| LA | 1 | 1 | ||
| LB | 0.363 | 1.564(0.597–4.096) | 0.316 | 2.153(0.480–9.652) |
| TN | 0.033 | 2.809(1.086–7.264) | 0.037 | 4.382(1.095–17.535) |
| HER2+ | 0.002 | 5.221(1.788–15.240) | 0.009 | 8.645(1.715–43.587) |
| CHD1L over-expression | 0.042* | 0.479 | ||
| Absense | 1 | 1 | ||
| Presence | 2.169(1.029–4.573) | 0.663(0.212–2.069) | ||
*, statistically significant.
Abbreviations: DFS, disease free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; LA, luminal A; LB, luminal B; TN, triple negative; HER2, human epidermal growth factor receptor 2.